Literature DB >> 21240468

Evidence-based toxicology - the toolbox of validation for the 21st century?

Thomas Hartung1.   

Abstract

Validation has become a primary driver of the evolution of toxicological methods. Agreement at OECD level currently requires validation of new approaches for consideration in test guideline development. Several examples of this exist. However, the toxicology in the 21(st) century movement, prompted by the 2007 NRC/NAS vision document, might lead to a revolutionary change in the toxicological toolbox. The challenge is whether the validation process, as it has been formalized over the last two decades, meets the needs for this paradigm shift.The concept of evidence-based medicine (EBM) has emerged from clinical medicine, which retrospectively assesses the evidence of adequacy of a given approach. This is not typically done in prospective studies - the equivalent of validation studies might be multicenter randomized trials. Evidently, where such unambiguous evidence is available, no other assessment is necessary. EBM, however, has developed procedures, including meta-analysis, to collect and evaluate all the available evidence where no such definitive study is available. The recent successful introduction of retrospective validation, i.e. the collection and evaluation of existing evidence from various sources, represents a step in this direction. Here, we will explore new toxicological approaches via evidence-based toxicology (EBT).

Mesh:

Year:  2010        PMID: 21240468     DOI: 10.14573/altex.2010.4.253

Source DB:  PubMed          Journal:  ALTEX        ISSN: 1868-596X            Impact factor:   6.043


  17 in total

Review 1.  Developmental neurotoxicity - challenges in the 21st century and in vitro opportunities.

Authors:  Lena Smirnova; Helena T Hogberg; Marcel Leist; Thomas Hartung
Journal:  ALTEX       Date:  2014       Impact factor: 6.043

2.  Pathways of Toxicity.

Authors:  Andre Kleensang; Alexandra Maertens; Michael Rosenberg; Suzanne Fitzpatrick; Justin Lamb; Scott Auerbach; Richard Brennan; Kevin M Crofton; Ben Gordon; Albert J Fornace; Kevin Gaido; David Gerhold; Robin Haw; Adriano Henney; Avi Ma'ayan; Mary McBride; Stefano Monti; Michael F Ochs; Akhilesh Pandey; Roded Sharan; Rob Stierum; Stuart Tugendreich; Catherine Willett; Clemens Wittwehr; Jianguo Xia; Geoffrey W Patton; Kirk Arvidson; Mounir Bouhifd; Helena T Hogberg; Thomas Luechtefeld; Lena Smirnova; Liang Zhao; Yeyejide Adeleye; Minoru Kanehisa; Paul Carmichael; Melvin E Andersen; Thomas Hartung
Journal:  ALTEX       Date:  2013-10-15       Impact factor: 6.043

Review 3.  Big-data and machine learning to revamp computational toxicology and its use in risk assessment.

Authors:  Thomas Luechtefeld; Craig Rowlands; Thomas Hartung
Journal:  Toxicol Res (Camb)       Date:  2018-05-01       Impact factor: 3.524

Review 4.  Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing.

Authors:  Uwe Marx; Tommy B Andersson; Anthony Bahinski; Mario Beilmann; Sonja Beken; Flemming R Cassee; Murat Cirit; Mardas Daneshian; Susan Fitzpatrick; Olivier Frey; Claudia Gaertner; Christoph Giese; Linda Griffith; Thomas Hartung; Minne B Heringa; Julia Hoeng; Wim H de Jong; Hajime Kojima; Jochen Kuehnl; Marcel Leist; Andreas Luch; Ilka Maschmeyer; Dmitry Sakharov; Adrienne J A M Sips; Thomas Steger-Hartmann; Danilo A Tagle; Alexander Tonevitsky; Tewes Tralau; Sergej Tsyb; Anja van de Stolpe; Rob Vandebriel; Paul Vulto; Jufeng Wang; Joachim Wiest; Marleen Rodenburg; Adrian Roth
Journal:  ALTEX       Date:  2016-05-15       Impact factor: 6.043

Review 5.  Mapping the human toxome by systems toxicology.

Authors:  Mounir Bouhifd; Helena T Hogberg; Andre Kleensang; Alexandra Maertens; Liang Zhao; Thomas Hartung
Journal:  Basic Clin Pharmacol Toxicol       Date:  2014-02-15       Impact factor: 4.080

6.  Integrated testing strategies for safety assessments.

Authors:  Thomas Hartung; Tom Luechtefeld; Alexandra Maertens; Andre Kleensang
Journal:  ALTEX       Date:  2013       Impact factor: 6.043

7.  Look back in anger - what clinical studies tell us about preclinical work.

Authors:  Thomas Hartung
Journal:  ALTEX       Date:  2013       Impact factor: 6.043

Review 8.  Biological and medical applications of a brain-on-a-chip.

Authors:  David Pamies; Thomas Hartung; Helena T Hogberg
Journal:  Exp Biol Med (Maywood)       Date:  2014-06-09

9.  Computer-aided design of carbon nanotubes with the desired bioactivity and safety profiles.

Authors:  Denis Fourches; Dongqiuye Pu; Liwen Li; Hongyu Zhou; Qingxin Mu; Gaoxing Su; Bing Yan; Alexander Tropsha
Journal:  Nanotoxicology       Date:  2015-11-02       Impact factor: 5.913

10.  Mechanistic validation.

Authors:  Thomas Hartung; Sebastian Hoffmann; Martin Stephens
Journal:  ALTEX       Date:  2013       Impact factor: 6.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.